This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis loses cost decision in Zentiva patent dispute at UPC

( July 31, 2025, 13:45 GMT | Official Statement) -- MLex Summary: Pharmaceutical company Novartis today lost the decision on legal cost compensation in the dispute regarding EP 2,501,384 with Zentiva entities at the UPC’s central division in Milan, due to insufficient evidence. Novartis had applied for a cost coverage of 38,000 euros for its international legal fees, which Zentiva contested. In the assessment, the court made use of examining individual cost items if the applicant’s submission lacks specific evidence. The court found Novartis’s evidence to be inadequate and rejected its confidentiality claim to withhold information. The Zentiva entities must each pay 3,000-euros — the amount they did not contest.The decision is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections